Mylan NV (NASDAQ: MYL) stock lost over 10.2% in the pre-market session of 27^th Feb, 2019 (Source: Google finance) after the company posted mixed results for the fourth quarter of FY 18. In Europe, net sales totaled approximately $4.2 billion representing mid-single-digit growth from prior year. The increase was a result of strong performance of the brands including Creon, DYMISTA and Influvac each with double-digit growth, new product sales and a favorable impact of foreign currency translation. In the Rest of World segment, net sales totaled approximately $3 billion, an increase of 7% from the prior year including headwinds in the foreign currency translation. This increase was primarily the result of new product sales across the region, the strong performance of our ARV Franchise, whereas Japan, Australia, and China also showed strength on higher volumes of existing products.

MYL in the fourth quarter of FY 18 has reported the adjusted earnings per share of $1.30, missing the analysts’ estimates for the adjusted earnings per share of $1.35, according to FactSet. The company had reported a 5 percent fall in the adjusted revenue to $3.08 billion in the fourth quarter of FY 18, beating the analysts’ estimates for revenue of $3.06 billion. The revenue fell due in part to costs related to issues and restructuring at its Morgantown, West Virginia, plant. The decline in total revenues and flat year-over-year adjusted EPS reflects solid execution for Europe and rest of world segment helping to offset the volatility in the North America segment where net sales were down 18% year-over-year impacted largely by three factors. First, the company experienced slower than expected uptake of our generic Copaxone even after reducing the price by more than 60%. Second approval of generic Advair did not occur in the timeline and lastly, MYL has rationalized a significant portion of the commodity generic business.

Mylan forecast adjusted earnings of $3.80 a share to $4.80 a share on revenue ranging of $11.5 billion to $12.5 billion, while analysts on average were predicting 2019 adjusted profit of $5.03 a share on revenue of $11.79 billion, according to FactSet. Mylan previously guided for 2019 the revenue to be in the range of $11.25 billion to $12.25 billion. The company has repeatedly trimmed its forecasts in a turbulent generic-drug market. Falling generic drug prices in the U.S. led the maker of copycat medicines last year to start reviewing strategic options such as a restructuring. MYL is looking to generate adjusted free cash flows between $1.9 billion and $2.3 billion.